Cantor Fitzgerald raised the firm’s price target on Harrow (HROW) to $94 from $76 and keeps an Overweight rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow Health: Strong Product Performance and Strategic Moves Justify Buy Rating
- Closing Bell Movers: CoreWeave down over 5% on lower sales, higher capex view
- Harrow Health Reports Strong Q3 2025 Financial Results
- Harrow reports Q3 core EPS 33c, consensus 29c
- HROW Earnings this Week: How Will it Perform?